The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Current International Perspectives on Hematopoietic Stem Cell Transplantation for Inherited Metabolic Disorders
Abstract
Inherited metabolic disorders (IMD) or inborn errors of metabolism are a diverse group of diseases arising from genetic defects in lysosomal enzymes or peroxisomal function. These diseases are characterized by devastating systemic processes affecting neurologic and cognitive function, growth and development, and cardiopulmonary status. Onset in infancy or early childhood is typically accompanied by rapid deterioration. Early death is a common outcome. Timely diagnosis and immediate referral to an IMD specialist are essential steps in management of these disorders. Treatment recommendations are based on the disorder, its phenotype including age at onset and rate of progression, severity of clinical signs and symptoms, family values and expectations, and the risks and benefits associated with available therapies such as allogeneic hematopoietic stem cell transplantation (HSCT). This review discusses indications for HSCT and outcomes of HSCT for selected IMD. An international perspective on progress, limitations, and future directions in the field is provided.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hematopoietic cell transplantation following myeloablative conditioning has been used to treat various genetic metabolic syndromes but is largely ineffective in diseases affecting the brain presumably due to poor and variable myeloid cell incorporation into the central nervous system.”
From Treatment of a genetic brain disease by CNS-wide microglia replacement (2022) · cites this paper as [6]
In the citing paper
“In addition to diseases of the bone marrow, allogeneic HCT has been used to treat systemic genetic syndromes (5, 6).”
From Treatment of a genetic brain disease by CNS-wide microglia replacement (2022) · cites this paper as [6]
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202
Moser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Aubourg, P., Blanche, S., Jambaqué, I., Rocchiccioli, F., Kalifa, G., Naud-Saudreau, C., Rolland, M.-O., Debré, M., Chaussain, J.-L., Griscelli, C., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006283222607 · Cited by 366
Shapiro, E., Krivit, W., Lockman, L., Jambaqué, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02629-5 · Cited by 329
Self-citationAdrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screening
Bezman, L., Moser, A. B., Raymond, G. V., Rinaldo, P., Watkins, P. A., Smith, K. D., Kass, N. E., & Moser, H. W. (2001) · Annals of Neurology · doi:10.1002/ana.101 · Cited by 324
Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy
Loes, D. J., Fatemi, A., Melhem, E. R., Gupte, N., Bezman, L., Moser, H. W., & Raymond, G. V. (2003) · Neurology · doi:10.1212/01.wnl.0000079050.91337.83 · Cited by 268
Ito, M., Blumberg, B. M., Mock, D. J., Goodman, A. D., Moser, A. B., Moser, H. W., Smith, K. D., & Powers, J. M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.10.1004 · Cited by 125
Cerebral X‐linked adrenoleukodystrophy in a girl with Xq27‐Ter deletion
Hershkovitz, E., Narkis, G., Shorer, Z., Moser, A. B., Watkins, P. A., Moser, H. W., & Manor, E. (2002) · Annals of Neurology · doi:10.1002/ana.10248 · Cited by 30
Research works printed but not linked: 103
- Fratantoni, 1969, The defect in Hurler and Hunter syndromes. II. Deficiency of specific factors involved in mucopolysaccharide degradation, Proc Natl Acad Sci U S A, 64, 360, 10.1073/pnas.64.1.360 · DOI
- Neufeld, 1991, Lysosomal storage diseases, Annu Rev Biochem, 60, 257, 10.1146/annurev.bi.60.070191.001353 · DOI
- Pfeffer, 1991, Targeting of proteins to the lysosome, Curr Top Microbiol Immunol, 170, 43
- Perry, 1991, Macrophages and the nervous system, Int Rev Cytol, 125, 203, 10.1016/S0074-7696(08)61220-6 · DOI
- Krivit, 1995, Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases, Cell Transplant, 4, 385, 10.1177/096368979500400409 · DOI
- Giulian, 1987, Ameboid microglia as effectors of inflammation in the central nervous system, J Neurosci Res, 18, 155, 10.1002/jnr.490180123 · DOI
- Hickey, 1991, Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation, Brain Pathol, 1, 97, 10.1111/j.1750-3639.1991.tb00646.x · DOI
- Kennedy, 1997, Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model, Blood, 90, 986, 10.1182/blood.V90.3.986 · DOI
- Hobbs, 1981, Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation, Lancet, 2, 709, 10.1016/S0140-6736(81)91046-1 · DOI
- Krivit, 1984, Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI), N Engl J Med, 311, 1606, 10.1056/NEJM198412203112504 · DOI
- Krivit, 1998, Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy, N Engl J Med, 338, 1119, 10.1056/NEJM199804163381605 · DOI
- Krivit, 1990, Treatment of late-infantile metachromatic leukodystrophy by bone marrow transplantation, N Engl J Med, 322, 28, 10.1056/NEJM199001043220106 · DOI
- Vellodi, 1997, Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres, Arch Dis Child, 76, 92, 10.1136/adc.76.2.92 · DOI
- Peters, 1998, Hurler syndrome. II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group, Blood, 91, 2601, 10.1182/blood.V91.7.2601 · DOI
- Staba, 2004, Cord-blood transplants from unrelated donors in patients with Hurler's syndrome, N Engl J Med, 350, 1960, 10.1056/NEJMoa032613 · DOI
- Boelens, 2007, Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure, Bone Marrow Transplant, 40, 225, 10.1038/sj.bmt.1705718 · DOI
- Boelens, 2009, EUROCORD, Inborn Error Working Party of EBMT and Duke University. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with Hurler syndrome, Biol Blood Marrow Transplant, 15, 618, 10.1016/j.bbmt.2009.01.020 · DOI
- Peters, 2004, Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999, Blood, 104, 881, 10.1182/blood-2003-10-3402 · DOI · Paper page
- Beam, 2007, Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy, Biol Blood Marrow Transplant, 13, 665, 10.1016/j.bbmt.2007.01.082 · DOI · Paper page
- Escolar, 2005, Transplantation of umbilical-cord-blood in babies with infantile Krabbe's disease, N Engl J Med, 352, 2069, 10.1056/NEJMoa042604 · DOI
- Grigull, 2005, Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis IH (M. Hurler), Bone Marrow Transplant, 35, 265, 10.1038/sj.bmt.1704786 · DOI
- Peters, 1996, Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome, Blood, 87, 4894, 10.1182/blood.V87.11.4894.bloodjournal87114894 · DOI
- Prasad, 2008, Emerging trends in transplantation of inherited metabolic diseases, Bone Marrow Transplant, 41, 99, 10.1038/sj.bmt.1705970 · DOI
- Prasad, 2008, Unrelated donor umbilical cord blood for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes, Blood, 112, 2979, 10.1182/blood-2008-03-140830 · DOI
- Grewal, 2005, Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome, Genet Med, 7, 143, 10.1097/01.GIM.0000154299.22120.6A · DOI
- Cox-Brinkman, 2006, Hematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome, Bone Marrow Transplant, 38, 17, 10.1038/sj.bmt.1705401 · DOI
- Tolar, 2008, Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome, Bone Marrow Transplant, 41, 531, 10.1038/sj.bmt.1705934 · DOI
- Wynn, 2009, Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients, J Pediatr, 154, 135, 10.1016/j.jpeds.2008.07.004 · DOI
- Aldenhoven, 2008, The clinical outcome of Hurler syndrome after stem cell transplantation, Biol Blood Marrow Transplant, 14, 485, 10.1016/j.bbmt.2008.01.009 · DOI
- Boelens, 2006, Trends in haematopoietic cell transplantation for inborn errors of metabolism, J Inherit Metab Dis, 29, 413, 10.1007/s10545-005-0258-8 · DOI
- Kurtzberg, 1996, Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients, N Engl J Med, 335, 157, 10.1056/NEJM199607183350303 · DOI
- Chen, 2005, Human umbilical cord blood progenitors: the potential of these hematopoietic cells to become neural, Stem Cells, 23, 1560, 10.1634/stemcells.2004-0284 · DOI
- Kogler, 2004, A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential, J Exp Med, 200, 123, 10.1084/jem.20040440 · DOI
- Meier, 2006, Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells, Pediatr Res, 9, 244, 10.1203/01.pdr.0000197309.08852.f5 · DOI
- Church, 2007, Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease, Bone Marrow Transplant, 39, 207, 10.1038/sj.bmt.1705569 · DOI
- Martin, 2006, Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases, Biol Blood Marrow Transplant, 12, 184, 10.1016/j.bbmt.2005.09.016 · DOI
- Stein, 2007, Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation, Eur J Pediatr, 166, 663, 10.1007/s00431-006-0298-6 · DOI
- Baxter, 2005, Marrow stromal cells from patients affected by MPS I differentially support haematopoietic progenitor cell development, J Inherit Metab Dis, 28, 1045, 10.1007/s10545-005-0136-4 · DOI
- Kakkis, 2001, Enzyme-replacement therapy in mucopolysaccharidosis I, N Engl J Med, 344, 182, 10.1056/NEJM200101183440304 · DOI
- Wraith, 2005, The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I, Expert Opin Pharmacother, 6, 489, 10.1517/14656566.6.3.489 · DOI
- Cimaz, 2006, Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome, Clin Exp Rheumatol, 24, 196
- Wraith, 2007, Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase), Pediatrics, 120, e37, 10.1542/peds.2006-2156 · DOI
- Aldenhoven, 2009, The musculoskeletal manifestations of lysosomal storage disorders, Ann Rheum Dis, 68, 1659, 10.1136/ard.2008.095315 · DOI
- Manger, 2007, Rheumatologic aspects of lysosomal storage diseases, Clin Rheumatol, 26, 335, 10.1007/s10067-006-0299-x · DOI
- Bergstrom, 1994, Long-term follow-up of a patient transplanted for Hunter's disease type IIB: a case report and literature review, Bone Marrow Transplant, 14, 653
- Coppa, 1995, Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): 2-year follow-up of the first Italian patient and review of the literature, Pediatr Med Chir, 17, 227
- Guffon, 2009, Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years, J Pediatr, 154, 733, 10.1016/j.jpeds.2008.11.041 · DOI
- Li, 1996, Biochemical and molecular analysis in a patient with the severe form of Hunter syndrome after bone marrow transplantation, Am J Med Genet, 64, 531, 10.1002/(SICI)1096-8628(19960906)64:4<531::AID-AJMG1>3.0.CO;2-S · DOI
- Peters, 2000, Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome), Bone Marrow Transplant, 25, 1097, 10.1038/sj.bmt.1702398 · DOI
- Vellodi, 1999, Long-term follow-up following bone marrow transplantation for Hunter disease, J Inherit Metab Dis, 22, 638, 10.1023/A:1005525931994 · DOI
- Mullen, 2000, Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia, Bone Marrow Transplant, 25, 1093, 10.1038/sj.bmt.1702397 · DOI
- Gungor, 1995, Sanfilippo disease type B. A case report and review of the literature on recent advances in bone marrow transplantation, Turk J Pediatr, 37, 157
- Vellodi, 1992, Bone marrow transplantation for Sanfilippo disease type B, J Inherit Metab Dis, 15, 911, 10.1007/BF01800232 · DOI
- Herskhovitz, 1999, Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up, J Inherit Metab Dis, 22, 50, 10.1023/A:1005447232027 · DOI
- Lee, 2000, Umbilical cord blood transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI), Bone Marrow Transplant, 26, 455, 10.1038/sj.bmt.1702528 · DOI
- Boehm, 1999, Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy, Mol Genet Metab, 66, 128, 10.1006/mgme.1998.2779 · DOI · Paper page
- Moser, 1999, Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls, Ann Neurol, 45, 100, 10.1002/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U · DOI
- Aubourg, 2003, Adrenoleukodystrophy: the most frequent genetic cause of Addison's disease, Horm Res, 59, 104
- Moser, 1997, Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy, Brain, 120, 1485, 10.1093/brain/120.8.1485 · DOI · Paper page
- O'Neill, 2001, ABCD1 translation-initiator mutation demonstrates genotype-phenotype correlation for AMN, Neurology, 57, 1956, 10.1212/WNL.57.11.1956 · DOI · Paper page
- Powers, 2001, The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria, J Neuropathol Exp Neurol, 60, 493, 10.1093/jnen/60.5.493 · DOI · Paper page
- Powers, 2000, Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy, J Neuropathol Exp Neurol, 59, 89, 10.1093/jnen/59.2.89 · DOI · Paper page
- Moser, 1991, Adrenoleukodystrophy, Endocrinol Metab Clin North Am, 20, 297, 10.1016/S0889-8529(18)30270-6 · DOI
- Moser, 1987, The adrenoleukodystrophies, Crit Rev Neurobiol, 3, 29
- Peters, 2003, Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines, Bone Marrow Transplant, 31, 229, 10.1038/sj.bmt.1703839 · DOI
- Loes, 1994, Adrenoleukodystrophy: a scoring method for brain MR observations, AJNR Am J Neuroradiol, 15, 1761
- Tolar, 2007, N-acetyl-L-cysteine improves outcome of advanced adrenoleukodystrophy, Bone Marrow Transplant, 39, 211, 10.1038/sj.bmt.1705571 · DOI
- Moser, 2003, Evaluation of the preventive effect of glyceryl trioleate-trierucate (“Lorenzo's oil”) therapy in X-linked adrenoleukodystrophy: results of two concurrent trials, Adv Exp Med Biol, 544, 369, 10.1007/978-1-4419-9072-3_47 · DOI
- Escolar, 2006, A staging system for infantile Krabbe disease to predict outcome after unrelated umbilical cord blood transplantation, Pediatrics, 118, e879, 10.1542/peds.2006-0747 · DOI
- Duffner, 2009, Newborn screening for Krabbe disease: the New York State model [comment], Pediatr Neurol, 40, 245, 10.1016/j.pediatrneurol.2008.11.010 · DOI
- Stillman, 1994, Serial MR after bone marrow transplantation in two patients with metachromatic leukodystrophy, AJNR Am J Neuroradiol, 15, 1929
- Shapiro, 1992, White matter dysfunction and its neuropsychological correlates: a longitudinal study of a case of metachromatic leukodystrophy treated with bone marrow transplant, J Clin Exp Neuropsychol, 14, 610, 10.1080/01688639208402848 · DOI
- Pridjian, 1994, Pre-symptomatic late-infantile metachromatic leukodystrophy treated with bone marrow transplantation, J Pediatr, 125, 755, 10.1016/S0022-3476(06)80177-0 · DOI
- Guffon, 1995, Juvenile metachromatic leukodystrophy: neurological outcome two years after bone marrow transplantation, J Inherit Metab Dis, 18, 159, 10.1007/BF00711755 · DOI
- Shapiro, 1994, Characteristics of the dementia in late-onset metachromatic leukodystrophy, Neurology, 44, 662, 10.1212/WNL.44.4.662 · DOI
- Navarro, 1996, Late juvenile metachromatic leukodystrophy treated with bone marrow transplantation: a 4-year follow-up study, Neurology, 46, 254, 10.1212/WNL.46.1.254 · DOI
- Kapaun, 1999, Slow progression of juvenile metachromatic leukodystrophy 6 years after bone marrow transplantation, J Child Neurol, 14, 222, 10.1177/088307389901400402 · DOI
- Malm, 1996, Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation, Bone Marrow Transplant, 17, 1003
- Koç, 2002, Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH), Bone Marrow Transplant, 30, 215, 10.1038/sj.bmt.1703650 · DOI
- Orchard, 2007, Hematopoietic cell therapy for metabolic disease, J Pediatr, 151, 340, 10.1016/j.jpeds.2007.04.054 · DOI
- Tolar, 2009, Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease, Bone Marrow Transplant, 43, 21, 10.1038/bmt.2008.273 · DOI
- Grewal, 2004, Effective treatment of alpha-mannosidosis by allogeneic hematopoietic stem cell transplantation, J Pediatr, 144, 569, 10.1016/j.jpeds.2004.01.025 · DOI
- Yamada, 1998, Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation, Bone Marrow Transplant, 21, 629, 10.1038/sj.bmt.1701141 · DOI
- Klein, 1995, Poor cognitive outcome of eleven children with Sanfilippo syndrome after bone marrow transplantation and successful engraftment, Bone Marrow Transplant, 15, S176
- Grewal, 2003, Continued neurocognitive development and prevention of cardiopulmonary complications after successful BMT for I-cell disease: a long-term follow-up report, Bone Marrow Transplant, 32, 957, 10.1038/sj.bmt.1704249 · DOI
- Bayever, 1992, Bone marrow transplantation for Niemann-Pick type IA disease, J Inherit Metab Dis, 15, 919, 10.1007/BF01800234 · DOI
- Lake, 1997, Bone marrow transplantation in late infantile Batten disease and juvenile Batten disease, Neuropediatrics, 28, 80, 10.1055/s-2007-973677 · DOI
- Jacobs, 2005, Allogeneic BMT followed by substrate reduction therapy in a child with subacute Tay-Sachs disease, Bone Marrow Transplant, 36, 925, 10.1038/sj.bmt.1705155 · DOI
- Ringdén, 1988, Longterm follow-up of the first successful bone marrow transplantation in Gaucher disease, Transplantation, 46, 66, 10.1097/00007890-198807000-00011 · DOI
- Hobbs, 1987, Beneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher's syndrome, Lancet, 1, 1111, 10.1016/S0140-6736(87)91673-4 · DOI
- Erikson, 1990, Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type, Acta Paediatr Scand, 79, 680, 10.1111/j.1651-2227.1990.tb11535.x · DOI
- Ringdén, 1995, Ten years' experience of bone marrow transplantation for Gaucher disease, Transplantation, 59, 864, 10.1097/00007890-199503000-00011 · DOI
- Erikson, 2006, Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease, Acta Paediatr, 95, 312, 10.1111/j.1651-2227.2006.tb02232.x · DOI
- Porteus, 2006, A look to future directions in gene therapy research for monogenic diseases, PLoS Genet, 2, 10.1371/journal.pgen.0020133 · DOI
- Biffi, 2004, Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells, J Clin Invest, 113, 1118, 10.1172/JCI200419205 · DOI
- Chung, 2007, Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice, Mol Genet Metab, 90, 181, 10.1016/j.ymgme.2006.08.001 · DOI
- Kobayashi, 2005, Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector, Mol Ther, 11, 776, 10.1016/j.ymthe.2004.10.006 · DOI
- Liu, 2005, Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice, Mol Ther, 11, 35, 10.1016/j.ymthe.2004.08.027 · DOI
- Zheng, 2003, Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow, Mol Genet Metab, 79, 233, 10.1016/S1096-7192(03)00116-1 · DOI
- Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 · DOI · Paper page
- Pardridge, 2005, Molecular biology of the blood-brain barrier, Mol Biotechnol, 30, 57, 10.1385/MB:30:1:057 · DOI
- Phinney, 2007, Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views, Stem Cells, 25, 2896, 10.1634/stemcells.2007-0637 · DOI
- Le Blanc, 2004, Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet, 363, 1439, 10.1016/S0140-6736(04)16104-7 · DOI · Paper page
Cited by
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Self-citationLysosomal storage diseases: from pathophysiology to therapy
Parenti, G., Andria, G., & Ballabio, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-122313-085916 · Cited by 404
Treatment of a genetic brain disease by CNS-wide microglia replacement
Shibuya, Y., Kumar, K. K., Mader, M. M.-D., Yoo, Y., Ayala, L. A., Zhou, M., Mohr, M. A., Neumayer, G., Kumar, I., Yamamoto, R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9945 · Cited by 126
Clinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
Filosto, M., Scarpelli, M., Tonin, P., Lucchini, G., Pavan, F., Santus, F., Parini, R., Donati, M. A., Cotelli, M. S., Vielmi, V., et al. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6572-9 · Cited by 64
Metadata
- Authors
- Boelens, J. J., Prasad, V. K., Tolar, J., Wynn, R. F., & Peters, C.
- Venue
- Pediatric Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 57
- Issue
- 1
- Pages
- 123-145
- ISSN
- 0031-3955
- Cited by
- 109
- References
- 9
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current International Perspectives on Hematopoietic Stem Cell Transplantation for Inherited Metabolic Disorders. https://app.cochat.ai/papers/10.1016/j.pcl.2009.11.004
- The paper
- Boelens, J. J., Prasad, V. K., Tolar, J., Wynn, R. F., & Peters, C. (2010). Current International Perspectives on Hematopoietic Stem Cell Transplantation for Inherited Metabolic Disorders. Pediatric Clinics of North America. https://doi.org/10.1016/j.pcl.2009.11.004